Global Parkinson’s Disease Market Report: 2016 Edition - New Report by Koncept Analytics

View Report Details Global Parkinson’s Disease Market Report ----------------------------------------2016

View Report Details Executive Summary 

Parkinson’s Disease (PD) is a chronic and progressive neurodegenerative or movement disorder which involves the malfunction and death of vital nerve cells in the brain, called neurons. Parkinson’s primarily affects neurons in an area of the brain called the “substantia nigra”. The early signs and symptoms may be mild and may go unnoticed initially. The cause of this disease is mainly unknown with no cure till date but there exist several treatment options such as medications and surgery.



The current treatment market for Parkinson’s disease has several unmet needs as no treatment has yet been successful in fully restoring the function that produces dopamine. However, the treatment currently only aims at controlling and relieving symptoms. The Parkinson’s disease treatment market remains flooded by both branded and generic drugs. The market is expected to experience fluctuations in branded sales due to patent expiries and subsequent entry of generics in the market. Several biologics are under development for the treatment of Parkinson’s along with possibility of developing “Stem Cell” as a treatment therapy.



The Parkinson’s disease market is expected to acquire modest growth driven by launch of new therapies and increasing rate of drug treatment due to increasing healthcare expenditure and ageing population. The major growth drivers of the Parkinson’s disease market includes rising level of toxin exposure, increasing life expectancy, rising male population worldwide, ageing population, healthcare expenditure and pesticide consumption. However, the growth of the market will also remain challenged by generic erosion, current treatment limitations and increasing risk of developing Melanoma.



The report, “Global Parkinson’s disease Market” analyzes the currently prevailing condition of the market along with its future scope of development. The specific markets of the U.S., the European Union and Japan are being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.

Growth of the Parkinson’s disease drug market is expected to be primarily driven by several factors inclusive of increasing Parkinson’s disease prevalence, rise in ageing population globally and increasing cost of treatment therapies…

Global Parkinson’s Disease Drug Market by Value (2010-2015E)  The global Parkinson’s disease drug market is estimated to have reached US$... billion in the year 2015, increasing from US$... billion in the previous fiscal year recording an annual growth of …%.

n ilo B $ S U

 The European Union accounted for the maximum share of …% in revenue of the global Parkinson’s disease drug market for the year 2014. The U.S. accounted for second largest share of …% followed by Japan that held …% share.

2010

2011

2012 Revenue

2013

2014

2015E

Annual Growth

Global Parkinson’s Disease Drug Market by Region (2014)

The EU*

The U.S.

 Both Dopamine agonists and COMT inhibitors are estimated to have held equal share of … % for the year 2015, followed by MAO inhibitors and Levodopa with expected share of …% and ….% respectively.

Japan

Others

Global Parkinson’s Disease Market by Drug Class (2015E)

DA Agonist

COMT Inhibitors

MAO Inhibitors

Levodopa

Others

The Parkinson’s disease market in the U.S. has high unmet needs in safety and efficacy, thus, significantly suggesting that currently the market is still served below par by the existing treatment options…

The U.S. Parkinson’s Disease Market by Value & Volume (2013-2020E)

n ilo M $ S U

n ilo M

 The U.S. Parkinson’s disease market reached US$... million in the year 2015, with a further estimation of reaching US$... million by the end of year 2020. In terms of prescription volume the market reached … million in the year 2015.  Both branded and generic drugs in the U.S. held equal share of …% of the overall revenue for the year 2015. The revenue share of generics will keep declining by the end of year 2017, recording an expected share of ..%.  In 2015, majority of the Parkinson’s patients in the U.S. were treated with MAO-Inhibitors with …% share of the total market followed by Levodopa/Carbidopa (gold standard) holding …% share.

2013

2014

2015

2016E

2017E

Revenue

2018E

2019E

2020E

Prescriptions

The U.S. Parkinson’s Disease Market Value by Category (2013-2017E)

2013

2014

2015 Generics

2016E Branded

The U.S. Parkinson’s Disease Market by Drug Class (2015)

2017E MAO-B Inhibitors

Levodopa/ Carbidopa

Dopamine Agonists

COMT Inhibitors

The Parkinson’s Disease treatment market can acquire modest growth in the coming years driven by the launch of new therapies and increasing drug treatment rates due to increasing healthcare expenditure and ageing population…

The U.S. Parkinson’s Branded Drugs Market by Volume/ Value (2013-2020E)  The Parkinson’s disease branded drugs market of the U.S. reached US$.. million in 2015, increasing from US$... million in the previous year recording an annual growth of …%. In terms of volume, the market reached … million prescriptions decreasing from .. million in the previous fiscal year.

n ilo M $ S U

n ilo M

 The drug market for Parkinson’s disease in the EU (Germany, France, the UK, Italy and Spain) reached US$... million declining from US$... million in the previous fiscal year.  The Parkinson’s disease market of Japan reached US$... million in the year 2015, increasing from US$... million in the previous fiscal year recording an annual growth of …%.

2013

2014

2015

2016E

Revenue

2017E

2018E

2019E

2020E

Prescriptions

Japan’s Parkinson’s Disease Drug Market by Value (2014/2015)

n ilo M $ S U

S U n ilo M $

European Parkinson’s Disease Drug Market by Value (2014/2015)

2014

2015

2014

2015

Contact Us: Details View Report These are abridged and sanitized sample pages from the comprehensive report on the “ Global Parkinson’s Disease Market ”.

To know more about this report or for any customized research requirement, please contact the following:

Koncept Analytics

Vikas Gupta BD Manager

CS-36, Second Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 T. +91-120-4130959 C: +91-9811715635 vikas@konceptanalytics.com

www.konceptanalytics.com